Last checked at 3 May 2019 07:00
Novacyt S.A.
("Novacyt" or the "Company")
Change of Adviser and Update on Directors' Disclosures
Paris, France and Camberley, UK - 3 May 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its Nominated Adviser and joint broker with immediate effect.
AIM Rule 17 disclosure
In accordance with AIM Rule 17 and Schedule Two (g) sub-paragraph (v) of the AIM Rules for Companies, the Company has been informed by Andrew Heath, Non-executive Director, that Integrated Healing Technologies, LLC a US company of which Dr Heath was a non-executive director filed a petition for bankruptcy on 9 July 2018 and entered into Chapter 7 liquidation bankruptcy on 21 February 2019.
Update to disclosures required by Schedule 2(g) of the AIM Rules for Companies
In addition to the directorships disclosed in the Company's admission document dated 18 October 2017, directors of the Company were, or had been in the past five years, at that time, directors of the following companies:
Director | Additional Directorships at Admission to AIM | Additional Directorships held within the 5 years prior to Admission to AIM |
James Wakefield | N/A | Lab 21 Limited |
Graham Mullis | Lab 21 Limited, Lab 21 Healthcare Limited, Primer Design Limited, Microgen Bioproducts Limited, Biotec Laboratories Limited, Selah Technologies Limited, Mercia Diagnostics Limited (subsequently dissolved), Lab21 Inc., Novacyt Asia Limited, Novacyt China Limited, Myconostica Limited | Lab 21 Diagnostics Services Limited, NP Tech Services Limited, Myconostica Trustee Company Limited |
Anthony Dyer | Primer Design Limited, Selah Technologies Limited (subsequently dissolved), Microgen Bioproducts Limited, Mercia Diagnostics Limited, Biotec Laboratories Limited, Lab 21 Limited, Lab 21 Healthcare limited, Lab21 Inc., Novacyt Asia Limited | N/A |
Edwin Snape | Sultan Scientific Limited
| Lab 21 Limited |
Jean-Pierre Crinelli | SCI Crinelli-Plougrescant, SCI Crinelli Fonciere, Alain Fresard Technologies-Micromecanique SAS | N/A |
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information, please refer to www.novacyt.com or contact:
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)
Matthew Johnson / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell/ Mary Whittow
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/ Mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information please refer to the website: www.novacyt.com